Group 1 - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the product to be marketed [1] - For the first half of 2025, Shanghai Pharmaceuticals' revenue composition is as follows: distribution accounts for 91.5%, industrial for 8.59%, retail for 2.97%, other businesses for 0.34%, and other for 0.08% [1] - As of the report date, Shanghai Pharmaceuticals has a market capitalization of 66.6 billion yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the company to market this product in the Philippines, which is expected to positively impact its overseas market expansion and provide valuable experience [1] Group 1 - The Hydroxychloroquine Sulfate Tablets are primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, and skin diseases exacerbated by sunlight [1] - The approval of the 200mg Hydroxychloroquine Sulfate Tablets signifies the company's qualification to sell this drug in the Philippine market [1] - This development is seen as a step forward for the company in expanding its international presence [1]

上海医药12月15日公告，公司下属常州制药厂有限公司的盐酸索他洛尔片收到国家药品监督管理局颁发 的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。 常州制药厂的盐酸索他 洛尔片通过仿制药一致性评价，有利于扩大该药品的市场份额，提升市场竞争力。 因受国家政策、市 场环境等不确定因素影响，该药品可能存在销售不达预期等情况，具有较大不确定性。 ...

盐酸索他洛尔片主要用于：1、转复，预防室上性心动过速，特别是房室结折返性心动过速，也可用于 预激综合征伴室上性心动过速。2、心房扑动，心房颤动。3、各种室性心律失常，包括室性早搏，持续 性及非持续性室性心动过速。4、急性心肌梗死并发严重心律失常。 格隆汇12月15日丨上海医药(601607.SH)公布，公司下属常州制药厂有限公司（称"常州制药厂"）的盐 酸索他洛尔片（称"该药品"）收到国家药品监督管理局颁发的《药品补充申请批准通知书》（通知书编 号：2025B05883），该药品通过仿制药质量和疗效一致性评价。 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., received a drug registration certificate from the Philippines Food and Drug Administration for Hydroxychloroquine Sulfate Tablets, allowing the product to be marketed [1] Group 1 - The approved drug, Hydroxychloroquine Sulfate Tablets, is primarily used for rheumatoid arthritis, juvenile chronic arthritis, discoid and systemic lupus erythematosus, as well as skin diseases exacerbated by sunlight [1]

（原标题：上海医药现2笔大宗交易 合计成交28.10万股） | 成交量 | 成交金 额 | 成交价 | 相对当日 收盘折溢 | 买方营业 | | | --- | --- | --- | --- | --- | --- | | （万 | | 格 | | | 卖方营业部 | | 股） | （万 | （元） | 价 | 部 | | | | 元） | | （%） | | | | 15.59 12.51 | 281.46 225.75 | 18.05 18.05 | 0.00 0.00 | 机构专用 机构专用 | 瑞银证券有限责任公司上海花园石桥路证券营业 部 瑞银证券有限责任公司上海花园石桥路证券营业 部 | 上海医药12月12日大宗交易平台共发生2笔成交，合计成交量28.10万股，成交金额507.21万元。成交价 格均为18.05元。从参与大宗交易营业部来看，机构专用席位共出现在2笔成交的买方或卖方营业部中， 合计成交金额为507.21万元，净买入507.21万元。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 证券时报•数据宝统计显示，上海医药今日收盘价为18.05元，上涨1.35%，日换手率为1 ...

| 交易日期 | 证券調移 | 证券代码 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 | | | | | 类出营业部 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-12 | 上海医药 | 601607 | 18.05 | 281.46 | 15.59 | 机构专用 | និង និងប្រទេស | 客 | | 2025-12-12 | 上海医药 | 601607 | 18.05 | 225.75 | 12.51 | 机构专用 | ​​​ | Ka | 12月12日，上海医药大宗交易成交28.1万股，成交额507.21万元，占当日总成交额的0.89%，成交价 18.05元，较市场收盘价18.05元持平。 ...

其中，拟用于治疗视神经脊髓炎的创新型CD20注射剂B001，拟用于治疗轻、中度脊髓型颈椎病的中药 1类新药参芪麝蓉丸均已完成III期临床试验全部受试者入组；拟用于治疗肌萎缩侧索硬化症（渐冻症） 的中药1类新药SRD4610，拟用于治疗急性缺血性脑卒中的化药1类新药SHPL-49，近期也都已开展III期 临床试验。 此外，上海医药携手高校及顶尖科研机构共同创立的生命科学创新孵化引擎"上海前沿"，自去年9月份 正式投入运营以来，已吸引了包括国家级生命研究院，拜耳、礼来等著名的跨国药企，以及上国投、上 海生物医药基金等在内的一大批研发创新机构、专业服务机构和科创企业入驻，形成创新要素加速集聚 的良好生态。 上海医药表示，未来将持续在创新研发领域投入，聚焦肿瘤、免疫、心血管、精神神经、消化代谢、抗 感染等临床需求迫切的领域，推动更多具有临床价值的创新药物上市；同时深化"产学研医资"协同创新 生态，加快创新成果转化。 （文章来源：新华财经） 新华财经上海12月12日电（记者杜康）上海医药集团股份有限公司（以下简称"上海医药"）又一款1类 创新药获批。记者获悉，上海上药信谊药厂有限公司申报的1类创新药苹果酸司妥吉仑片已于 ...

Core Viewpoint - Shanghai Pharmaceuticals has received approval for its innovative drug, Sitojilun, aimed at treating primary hypertension, marking a significant achievement in its commitment to independent innovation in the pharmaceutical industry [1][2]. Group 1: Product Approval and Market Strategy - The innovative drug Sitojilun (SPH3127), a new generation oral non-peptide small molecule renin inhibitor, has been approved for market launch, addressing unmet clinical needs in hypertension treatment [1]. - Shanghai Pharmaceuticals has established a comprehensive distribution network covering over 80,000 medical institutions across 25 provinces, municipalities, and autonomous regions in China, ensuring effective market access for Sitojilun [1]. Group 2: Research and Development Investment - In 2024, Shanghai Pharmaceuticals plans to invest 2.818 billion yuan in R&D, positioning itself among the industry leaders in investment intensity [2]. - As of the end of Q3 2025, the company has submitted 57 new drug applications for clinical trials, with 45 of these being innovative drugs, demonstrating a robust pipeline and commitment to long-term innovation [2]. Group 3: Collaborative Innovation Ecosystem - The company has established the Shanghai Frontier Life Science Innovation Center to foster collaboration with top universities and research institutions, creating an open innovation ecosystem [3]. - Since its launch in September of last year, the center has attracted numerous renowned research institutions and pharmaceutical companies, enhancing the innovation landscape [3]. - Shanghai Pharmaceuticals aims to continue investing in R&D focused on urgent clinical needs in areas such as oncology, immunology, cardiovascular health, and infectious diseases, with the goal of transforming innovative results into marketable products [3].

格隆汇12月11日｜中邮证券研报指出，上海医药商业板块稳健增长，Q3减值影响利润，看好创新业务 驱动成长。公司医药商业业务继续保持增长韧性，优势区域增长态势强劲，器械大健康业务表现亮眼， 新零售战略调整成效显现，CSO业务规模再创新高，创新药产品结构持续优化，供应链服务面向专业化 与价值链高端延伸。2025Q1-3公司创新药业务实现销售收入407亿元，同比增长超过25%；进口总代业 务实现销售收入276亿元，同比增长超过14%；器械大健康业务实现销售收入339.88亿元，同比增长超 过4%。截至2025年9月30日，公司提交临床试验申请获得受理及进入后续临床试验阶段的新药管线共计 57项，包括创新药管线45项。维持"买入"评级。 ...